Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Show more
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.54 | 4.50951683748 | 34.15 | 36.72 | 33.82 | 1874868 | 35.21937308 | CS |
| 4 | 7.21 | 25.316011236 | 28.48 | 36.72 | 28.3 | 2626615 | 34.24529775 | CS |
| 12 | 9.82 | 37.9590258987 | 25.87 | 36.72 | 25.12 | 2116323 | 30.0796617 | CS |
| 26 | 15.26 | 74.6940773372 | 20.43 | 36.72 | 20.14 | 1919037 | 27.04676011 | CS |
| 52 | 14.09 | 65.2314814815 | 21.6 | 36.72 | 19.2 | 2063357 | 24.55514364 | CS |
| 156 | 18.35 | 105.824682814 | 17.34 | 36.72 | 14.87 | 2330550 | 20.61921022 | CS |
| 260 | 18.91 | 112.693682956 | 16.78 | 36.72 | 13.67 | 2383743 | 20.7710985 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
